Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 11Glioma 4Sarcoma, Ewing 2Recurrence 2Medulloblastoma 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Sarcoma 1SCLC, Extensive Stage 1Rhabdomyosarcoma 1Primary Glioblastoma 1Pancreatic Neoplasms 1Osteosarcoma 1Melanoma 1Lymphoma, Follicular 1Hypoxia 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Astrocytoma 1Advanced Glioblastoma 1

Interventions

Carboplatin 12pembrolizumab 8Paclitaxel 8Cyclophosphamide 8toripalimab 4sacituzumab govitecan 4olaparib 4Epirubicin 4Drug Therapy 4Doxorubicin 4eribulin 3Capecitabine 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2Radiotherapy 2Injections 2Gemcitabine 2taxane 1poly ICLC 1pirfenidone 1palbociclib 1ivarmacitinib 1inavolisib 1fludarabine 1daratumumab 1camrelizumab 1axatilimab 1anlotinib 1aldesleukin 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Triple Negative Breast Neoplasms × Temozolomide × Clear all
NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡